Asia-Pacific Soft Tissue Repair Market 2021-2028

MARKET OUTLOOK

Based on this analysis, the soft tissue repair market in the Asia-Pacific is likely to rise with a CAGR of 6.86% over the forecast years from 2021 to 2028. Japan, India, China, Australia & New Zealand, ASEAN countries, South Korea, and Rest of Asia-Pacific together shape the market in this region.

According to statistics, cardiovascular disease is the primary cause of death among people in New Zealand, responsible for 40% of all mortalities. It is also a major cause of disability. This growing incidence of heart disease is expected to boost the demand for soft tissue repair in the country. In addition, successful collaborations between major companies and national organizations for reducing the risks of congenital heart diseases are expected to raise the demand for soft tissue repair patches here.

Ongoing research associated with developing cardiovascular & soft tissue repair patches featured with endogenous stem cells is estimated to spur market growth during the forecast period. In Australia, the National Health and Medical Research Council (NHMRC) provides regulated policies with a well-established research framework, which is boosting the demand for soft tissue repair products, thus enabling the market growth.

In India, the improvements in the healthcare infrastructure and the rise in healthcare expenditure to overcome patients’ unmet medical needs are expected to boost the demand for soft tissue repair products, which, in turn, will foster the market in the country. Besides, the high rate of incidence of unintentional trauma injuries has also triggered the development of the country’s soft tissue repair market.

COMPETITIVE OUTLOOK

The leading players in the soft tissue repair market include Allergan, Boston Scientific Corporation, Johnson & Johnson, Integra Lifesciences Corporation, Bard Peripheral Vascular Inc, Organogenesis Inc, Zimmer Biomet Inc, and Baxter International Inc.